
First alternative to surgery for proptosis

Gains two new orphan medicines through the $800m deal

Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”

But firm says latest deal 'significantly undervalues' Depomed

Horizon wants to add Depomed’s pain therapies and CNS drugs to its products

Israeli firm has already made multiple informal bids

Sources also claim the Delaware-based firm is being chased by Gilead Sciences and Teva

Allegedly made a £12.4bn takeover bid for the Swiss biopharma

French immuno-oncology biotech reported to be next on pharma giant's hit list

There is much debate over the value of the company’s shares